Figure 1 Identification of anti-HLA antibodies

Slides:

Advertisements

Similar presentations

PRA = 36% (21/58) Anti-A11 and B44.

Advertisements

Acceptable mismatches based on structural epitopes on HLA molecules Toulouse, April 2, 2008.

Objectives Overview of HLA genes and their function

Reference: Gloor J, Stegall MD

Donor Matching of Kidney Transplantation

Evan P. Kransdorf, MD, PhD, Michelle M. Kittleson, MD, PhD, Jignesh K

Hong Kong Workshop Lecture 3 Antigenicity of HLA-DRDQDP Epitopes

2 Renal Unit, Belfast City Hospital, Belfast, BT9 7AB

Hong Kong Workshop Lecture 8 HLA Epitopes and Acceptable Mismatches for Sensitized Transplant Patients.

Major Histocompatibility Complex

Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation Johann Pratschke, Duska Dragun, Ingeborg A. Hauser,

Living unrelated donor kidney transplantation

Single Antigen Beat Assay (Luminex) Allows Detection of Immunised Patients with an Increased Risk for Long Term Graft Survival Prior to Transplantation.

Kidney allocation to highly sensitized patients

Michael D. Gautreaux, Barry I. Freedman Kidney International

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 6 Effects of adiponectin on podocyte function

Marcelo Pando UNOS Region 5 Collaborative March, 2017

Figure 6 Differences in glycaemic control with the study drug

Nat. Rev. Nephrol. doi: /nrneph

Volume 78, Issue 2, Pages (July 2010)

Nat. Rev. Nephrol. doi: /nrneph

Hong Kong Workshop Lecture 6 Epitope Specificities of HLA Antibodies Tested in Ig- and C1q-Binding Assays and CDC.

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 3 Putative actions of glucagon-like peptide 1 (GLP-1)

Nat. Rev. Nephrol. doi: /nrneph

Volume 79, Issue 6, Pages (March 2011)

Figure 2 Expression of complement activation products in renal samples

Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 2 Three distinct mechanisms of activation of

Figure 1 The burden of chronic kidney disease (CKD)

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Glomerular pathology in mice and humans with diabetic nephropathy Figure 2 | Glomerular pathology in mice and humans with diabetic nephropathy.

Figure 5 Comparison of outcomes with belimumab or rituximab therapy

Figure 1 Acute kidney injury and chronic kidney disease

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 Model of changes in the serum levels

Figure 2 Prevention of antigen–antibody

Nat. Rev. Nephrol. doi: /nrneph

Towards epitope matching in kidney allocation

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Figure 6 Schematic of an analysis of a new biopsy

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Emerging models of antibody-mediated rejection (ABMR) and

Volume 86, Issue 5, Pages (November 2014)

Figure 4 The molecular configuration of the CD20 molecule

Volume 73, Issue 5, Pages (March 2008)

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Jayme E. Locke, MD, MPH American Journal of Kidney Diseases

Nat. Rev. Nephrol. doi: /nrneph

during the alloimmune response

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Chapter 4: Red cell transfusion to treat anemia in CKD

Living unrelated donor kidney transplantation

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Patient, facility, health-care system and industry factors

Figure 3 Preventive strategies for CSA-AKI

Figure 4 The relationship between the time-dependent changes in the expression of immunoglobulin, mast cell, acute kidney injury (AKI), and fibrillar collagen.

Figure 4 Intracellular distribution and

Does rituximab help in HLA desensitization for kidney transplantation?

Figure 3 Determination of the primary site

Presentation transcript:

Figure 1 Identification of anti-HLA antibodies Figure 1 | Identification of anti-HLA antibodies. Traditional cell-based, low-resolution techniques have been the standard method for identification of anti-HLA antibodies in the sera of transplant candidates, but are dependent on the availability of specific cell types and cell viability. Solid-phase testing of sera for HLA antibodies now enables precise identification of each individual HLA antigen against which a patient is sensitized, using techniques based on the Luminex® bead-based multiplex assay principle. The Calculated Panel Reactive Antibody value can be determined from the data obtained from solid-phase assays and is the percentage of historical kidney donors who express any HLA antigen reported as unacceptable because of the patient's antibody specificities. CDC, complement dependent cross-match. Permission obtained from © 2013 Dheda et al.; licensee InTech. Dheda, S. et al. in Current Issues and Future Direction in Kidney Transplantation 1st edn Vol. 1 Ch. 5 (ed. Rath, T.) 105–131 (InTech, 2013). Michael Cecka, J. (2016) Survival benefits of incompatibleliving donor kidney transplants Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.55